Pfizer, Valneva post mixed results for Lyme disease vaccine

AI Briefing

• – Pfizer's RSV vaccine trial shows positive results, Valneva's Lyme vaccine trial mixed.
• – Valneva's Lyme vaccine trial shows improved efficacy in older adults, but concerns over safety.
• – Pfizer's RSV vaccine is expected to be submitted for EUA in Q2 2026.